NR4A2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL45030	0.63	8/20
SCHEMBL71432	0.53	8/20
Oxaprozin (SCHEMBL3286)	1.00	7/20
SCHEMBL50925	0.42	7/20
SCHEMBL70381	0.58	4/20
SCHEMBL70573	0.58	4/20
SCHEMBL70429	0.53	4/20
SCHEMBL68630	0.46	4/20
SCHEMBL70011	0.44	4/20
Linoleic Acid (SCHEMBL7067)	1.00	3/20
Arachidonic Acid (SCHEMBL16162)	1.00	3/20
Arachidonic Acid (SCHEMBL16163)	1.00	3/20
SCHEMBL19452	1.00	3/20
Arachidonic Acid (SCHEMBL23768)	1.00	3/20
Alprostadil (SCHEMBL33317)	1.00	3/20
Gamolenic Acid (SCHEMBL19418)	0.96	3/20
SCHEMBL21763	0.59	3/20
SCHEMBL21764	0.58	3/20
SCHEMBL60987	0.55	3/20
SCHEMBL60487	0.55	3/20

Clinical trials — most relevant to NR4A2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Chronic Effects of Estrogen in Microcirculation	PHASE4	COMPLETED
The Use of Inhaled Corticosteroids in the Treatment of Asthma is Children in the Emergency Room	PHASE2/PHASE3	COMPLETED
Effects of Advair® in Outpatients With Chronic Obstructive Pulmonary Disease (COPD) Acute Exacerbation	PHASE3	COMPLETED
Fibrates in Pediatric Cholestasis	PHASE2	COMPLETED
N-DOSE AD: A Dose Optimization Trial of Nicotinamide Riboside in Alzheimer's Disease	PHASE2	COMPLETED
N-DOSE: A Dose Optimization Trial of Nicotinamide Riboside in Parkinson's Disease	PHASE2	COMPLETED
A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.	PHASE2	UNKNOWN
Preoperative Bexarotene Treatment for Cushing's Disease	PHASE1/PHASE2	UNKNOWN
A Study of Bezafibrate in Mitochondrial Myopathy	PHASE2	COMPLETED
Oral NRX 194204 Study in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)	PHASE2	UNKNOWN
Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer	PHASE1/PHASE2	COMPLETED
The PROMISE Study: Duavee in Women With DCIS	PHASE2	COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
Safety Study of the Effect of Scelectium Tortuosum (as Zembrin®)in Aged Normals	PHASE1	COMPLETED
Meclizine for Hepatocellular Carcinoma	PHASE1	COMPLETED
The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease	nan	COMPLETED
RORC Genetic Polymorphism of Rheumatoid Arthritis	nan	COMPLETED
The Role of Programmed Death Ligand -1 (Pdl-1) in Lung Cancer	nan	COMPLETED
Prognostic Value of Vitamin D Levels in Egyptian Females With Breast Cancer	nan	UNKNOWN
Study IL- 35 Level and Fibronectin Type Ⅲ Domain Containing Protein 5 \ Irsin (FNDC5 rs3480) Gene Variations in Chronic Hepatitis B.	nan	UNKNOWN
Comparison of Salivary Biormarkers Levels With Periodontal Clinical Parameters in Smokers and Non-Smokers With Different Periodontal Diseases	nan	COMPLETED
Molecular Mechanisms of Exercise Benefits to Insulin Resistant People	nan	COMPLETED
Potential Role of Inflammasome NLRP3 And IL-1B Gene Expression in COVID-19 Patients: Impact of Ferretin and D -Dimer.	nan	UNKNOWN
Steroid Treatment of Idiopathic Nephrotic Syndrome	nan	COMPLETED
Clinical and Basic Research on the Necessity of Scar Tissue Resection During Intrauterine Adhesions	nan	UNKNOWN
Replacement of Vitamin D in Patients With Active Tuberculosis	nan	COMPLETED
Personalised Pharmacological Approach to the Tapering of Corticosteroid Doses in Systemic Lupus Patients Treated With Prednisone	nan	COMPLETED
Immunolocalization of 1,25,Dihydroxyvitamin D3 in Aggressive Periodontitis Patients	nan	COMPLETED
Novel Biomarkers in Inflammatory Bowel Disease	nan	COMPLETED
Expression of Steroid Receptors in Endometrium	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a NR4A2 binder may also engage these)

Protein	Name	Similarity
Q07917	—	1.000	Q07917 →
A4IIG7	—	1.000	A4IIG7 →
Q5R5Y4	—	1.000	Q5R5Y4 →
Q06219	—	1.000	Q06219 →
Q08E53	—	1.000	Q08E53 →
P28700	—	0.995	P28700 →
P06211	—	0.995	P06211 →
P45448	—	0.995	P45448 →
Q64249	—	0.995	Q64249 →
Q04913	—	0.994	Q04913 →
Q9QWM1	—	0.994	Q9QWM1 →
Q08E02	—	0.994	Q08E02 →
P51129	—	0.994	P51129 →
P06212	—	0.994	P06212 →
P49883	—	0.994	P49883 →
Q63503	—	0.993	Q63503 →
Q63504	—	0.993	Q63504 →
Q9QZB6	—	0.993	Q9QZB6 →
O45436	—	0.993	O45436 →
A0JNE3	—	0.993	A0JNE3 →
Q6GN21	—	0.993	Q6GN21 →
Q9XYB7	—	0.993	Q9XYB7 →
P49867	—	0.993	P49867 →
NR5A2	Nuclear receptor subfamily 5 group A member 2	0.993	landscape →
P50569	—	0.993	P50569 →
Q9PU65	—	0.993	Q9PU65 →
P51128	—	0.993	P51128 →
NR4A3	Nuclear receptor subfamily 4 group A member 3	0.993	landscape →
Q9XSB5	—	0.993	Q9XSB5 →
P81559	—	0.993	P81559 →